Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.34 |
| ▸ | MBOAT4 | Q96T53 | 2/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL901326 | 0.98 | CDK5 (0.40) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL332530 | 0.98 | CDK5 (0.40) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL3825 | 0.98 | CDK5 (0.40) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| Water SCHEMBL1070875 | 0.97 | CDK5 (0.39) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL789094 | 0.97 | CDK5 (0.39) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL27882040 | 0.97 | CDK5 (0.39) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| Water SCHEMBL1888091 | 0.97 | CDK5 (0.39) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| Water SCHEMBL3935755 | 0.97 | CDK5 (0.39) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| Cyanide SCHEMBL28515924 | 0.94 | CDK5 (0.38) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL17856475 | 0.92 | NR1I3 (0.40) | CDK5CDK5R1NR1I3GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537094-B1 | Methods for converting taxane amides to paclitaxel or other taxanes | PHYTON HOLDINGS LLC (US) | 2014-07-02 | — | — | EP | claimed |
| US-7605278-B2 | Protecting the hydroxyl of a taxane amide; reducing the amide with a transition metalcompound; removing the metal; acidolysis to form a taxane amine salt in solution;adding solvent to solidify; convert the amine salt into paclitaxel or other taxanes | NATURAL PHARMACEUTICALS, INC. (US) | 2009-10-20 | — | — | US | claimed |
| EP-1599457-A4 | METHOD AND COMPOSITION FOR PREPARING A COMPOUND USING A BENZOLATING AGENT ESSENTIALLY FREE OF RING CHLORINATION | NATURAL PHARMACEUTICALS INC (US) | 2008-05-07 | — | — | EP | claimed |
| US-20080051589-A1 | Methods And Compositions For Converting Taxane Amides To Paclitaxel Or Other Taxanes | NATURAL PHARMACEUTICALS, INC. (US) | 2008-02-28 | — | — | US | claimed |
| US-20060035962-A1 | Method and compositions for preparing a compound using a benzoylating agent essentially free of ring chlorination | NATURAL PHARMACEUTICALS, INC. | 2006-02-16 | — | — | US | claimed |
| EP-1599457-A2 | METHOD AND COMPOSITION FOR PREPARING A COMPOUND USING A BENZOLATING AGENT ESSENTIALLY FREE OF RING CHLORINATION | Natural Pharmaceuticals, Inc. (US) | 2005-11-30 | — | — | EP | claimed |
| EP-1537094-A2 | METHODS AND COMPOSITIONS FOR CONVERTING TAXANE AMIDES TO PACLITAXEL OR OTHER TAXANES | Natural Pharmaceuticals, Inc. (US) | 2005-06-08 | — | — | EP | claimed |
| WO-2004068930-A2 | METHOD AND COMPOSITION FOR PREPARING A COMPOUND USING A BENZOLATING AGENT ESSENTIALLY FREE OF RING CHLORINATION | NATURAL PHARMACEUTICALS INC. (US) | 2004-08-19 | — | — | WO | claimed |
| WO-2004013096-A2 | METHODS AND COMPOSITIONS FOR CONVERTING TAXANE AMIDES TO PACLITAXEL OR OTHER TAXANES | NATURAL PHARMACEUTICALS INC. (US) | 2004-02-12 | — | — | WO | claimed |
| CN-106580880-A | Stable cabazitaxel particle redispersible system | 深圳海王医药科技研究院有限公司 | 2017-04-26 | — | — | CN | disclosed |
| CN-104490797-A | Multiphase-stable albumin conjunction type cabazitaxel | SHENZHEN NEPTUNUS PHARMACEUTIC | 2015-04-08 | — | — | CN | disclosed |
| EP-1537094-B1 | Methods for converting taxane amides to paclitaxel or other taxanes | PHYTON HOLDINGS LLC (US) | 2014-07-02 | — | — | EP | disclosed |
| US-7906661-B2 | Semi-synthetic conversion of paclitaxel to docetaxel | CHATHAM BIOTEC, LIMITED (CA) | 2011-03-15 | — | — | US | disclosed |
| US-7605278-B2 | Protecting the hydroxyl of a taxane amide; reducing the amide with a transition metalcompound; removing the metal; acidolysis to form a taxane amine salt in solution;adding solvent to solidify; convert the amine salt into paclitaxel or other taxanes | NATURAL PHARMACEUTICALS, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| WO-2004068930-A3 | METHOD AND COMPOSITION FOR PREPARING A COMPOUND USING A BENZOLATING AGENT ESSENTIALLY FREE OF RING CHLORINATION | NATURAL PHARMACEUTICALS INC (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004068930-A2 | METHOD AND COMPOSITION FOR PREPARING A COMPOUND USING A BENZOLATING AGENT ESSENTIALLY FREE OF RING CHLORINATION | NATURAL PHARMACEUTICALS INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004068930-A2 | METHOD AND COMPOSITION FOR PREPARING A COMPOUND USING A BENZOLATING AGENT ESSENTIALLY FREE OF RING CHLORINATION | NATURAL PHARMACEUTICALS INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004013096-A3 | METHODS AND COMPOSITIONS FOR CONVERTING TAXANE AMIDES TO PACLITAXEL OR OTHER TAXANES | NATURAL PHARMACEUTICALS INC (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004013096-A2 | METHODS AND COMPOSITIONS FOR CONVERTING TAXANE AMIDES TO PACLITAXEL OR OTHER TAXANES | NATURAL PHARMACEUTICALS INC. (US) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004013096-A2 | METHODS AND COMPOSITIONS FOR CONVERTING TAXANE AMIDES TO PACLITAXEL OR OTHER TAXANES | NATURAL PHARMACEUTICALS INC. (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051589-A1 | Methods And Compositions For Converting Taxane Amides To Paclitaxel Or Other Taxanes | CA1, CA3, TERT | CDK5 1694/4885CDK5R1 2805/4885NR1I3 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.